Fig. 1: CINSARC in cohort 1. | Modern Pathology

Fig. 1: CINSARC in cohort 1.

From: CINSARC signature outperforms gold-standard TNM staging and consensus molecular subtypes for clinical outcome in stage II–III colorectal carcinoma

Fig. 1Fig. 1

PFI (A) and OS (B) analyses according to CINSARC classification for stage II–III CRC patients; PFI (C) and OS (D) analyses according to CINSARC classification for stage II–III CRC patients without adjuvant treatment; PFI (E) and OS (F) analyses according to CINSARC classification for stage II–III CRC patients with adjuvant treatment; PFI (G) and OS (H) analyses according to CINSARC classification for stage II–III CRC patients with and without adjuvant treatment in cohort 1.

Back to article page